Related Experiment Video
Updated: Jun 18, 2026
A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
Effects of acute 3,4-methylenedioxymethamphetamine on sleep and daytime sleepiness in MDMA users: a preliminary study
Surilla Randall1, Chris-Ellyn Johanson, Manuel Tancer
1Sleep Disorders & Research Center Henry Ford Health System, Detroit, Michigan 48202, USA. srandal1@hfhs.org
Study Objective:
3,4-Methylenedioxymethamphetamine (MDMA) affects monoamine neurotransmitters that play a critical role in sleep and daytime alertness. However, the acute effects of MDMA on sleep and daytime sleepiness have not been studied under placebo-controlled conditions. This study was designed to establish the effects of acute MDMA or placebo administration and sleep restriction on sleep and daytime sleepiness.
Design:
Participants with a history of MDMA use were studied on 3 sessions of 3 nights (baseline, treatment, and recovery) and 2 days (following night 2 and 3) per session. On treatment nights (night 2), participants received placebo or 2 mg/kg of MDMA or underwent a restricted bed schedule with placebo. Sleep restriction was a positive control to compare sleep loss and consequent sleepiness associated with MDMA use. The scheduled sleep period was 8 hours long on nonrestricted nights, and standard sleep recordings and daytime sleepiness tests were conducted. Age-matched controls received 1 night and day of standard sleep and daytime sleepiness testing.
Setting:
Sleep laboratory.
Participants:
Seven recreational MDMA-users and 13 matched control subjects.
Measurements And Results:
Acute MDMA shortened sleep primarily by increasing sleep latency, and it reduced stage 3/4 sleep and suppressed rapid eye movement (REM) sleep. The MDMA-reduced sleep time was not associated with increased daytime sleepiness the following day, as was seen in the sleep-restriction condition. Compared with control subjects, the MDMA users on the first night in the laboratory had shorter total sleep times and less stage 3/4 sleep. Average daily sleep latency on daytime sleepiness tests the day after nighttime placebo administration was increased in MDMA users compared with the control subjects, and MDMA users had an elevated number of sleep-onset REM periods on these tests, compared with control subjects.
Conclusions:
Acute MDMA administration disrupts sleep and REM sleep, specifically, without producing daytime sleepiness such as sleep restriction does. Compared with control subjects, recreational MDMA users showed evidence of hyperarousal and impaired REM function. The mechanism behind these effects is likely due to the deleterious effects of MDMA on catecholamines.
Insights
Acute MDMA (3,4-Methylenedioxymethamphetamine) disrupts sleep architecture, reducing sleep time and REM sleep, but does not cause daytime sleepiness. Recreational MDMA users exhibit hyperarousal and impaired REM sleep compared to controls.
Area of Science:
- Neuroscience
- Sleep Medicine
- Psychopharmacology
Background:
- 3,4-Methylenedioxymethamphetamine (MDMA) impacts monoamine neurotransmitters crucial for sleep and alertness.
- Previous studies have not rigorously examined the acute effects of MDMA on sleep and daytime sleepiness under placebo-controlled conditions.
Purpose of the Study:
- To investigate the acute effects of MDMA administration and sleep restriction on sleep patterns and daytime sleepiness.
- To compare these effects with placebo and assess differences in recreational MDMA users versus controls.
Main Methods:
- A placebo-controlled study involving three sessions (baseline, treatment, recovery) with sleep recordings and daytime sleepiness tests.
- Participants received either placebo or 2 mg/kg MDMA, or underwent sleep restriction as a positive control.
- Seven recreational MDMA users and 13 age-matched controls were studied in a sleep laboratory.
Main Results:
- Acute MDMA administration shortened sleep by increasing sleep latency and reducing stage 3/4 and REM sleep.
- Unlike sleep restriction, MDMA-induced sleep changes were not associated with increased daytime sleepiness.
- MDMA users, compared to controls, showed shorter total sleep time, less stage 3/4 sleep, increased sleep latency, and more sleep-onset REM periods.
Conclusions:
- Acute MDMA disrupts sleep architecture, particularly REM sleep, without inducing the daytime sleepiness observed with sleep restriction.
- Recreational MDMA users demonstrated signs of hyperarousal and impaired REM sleep function compared to control subjects.
- The observed effects are likely attributable to MDMA's impact on catecholamine systems.
Related Concept Videos
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:24Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...
01:22CNS Stimulants: Psychedelic Agents
01:13Insufficient Sleep and Sleep Deprivation
Sleep deprivation is a more severe form of sleep loss...
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
01:29Stimulants
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...